Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Co-Diagnostics Engages Maxim Group To Explore Strategic Options For Indian Joint Venture CoSara, Including Potential SPAC Merger

Author: Benzinga Newsdesk | November 05, 2025 09:08am

Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular diagnostic tests, today announced that it has engaged Maxim Group LLC ("Maxim") as its exclusive financial advisor to assist the Company in identifying potential strategic alternatives for the Company's Indian joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), including a merger with a Special Purpose Acquisition Company ("SPAC") or similar entity listed on a U.S. national securities exchange.

Posted In: CODX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist